000110465915080476txt 20151120 000110465915080476hdrsgml 20151120 20151120165705 accession number 000110465915080476 conformed submission type sc 14d9a public document count 3 filed date 20151120 date change 20151120 subject company company data company conformed name depomed inc central index key 0001005201 standard industrial classification pharmaceutical preparation 2834 irs number 943229046 state incorporation ca fiscal year end 1231 filing value form type sc 14d9a sec act 1934 act sec file number 00553683 film number 151247249 business address street 1 7999 gateway blvd street 2 suite 300 city newark state ca zip 94560 business phone 5107448000 mail address street 1 7999 gateway blvd street 2 suite 300 city newark state ca zip 94560 filed by company data company conformed name depomed inc central index key 0001005201 standard industrial classification pharmaceutical preparation 2834 irs number 943229046 state incorporation ca fiscal year end 1231 filing value form type sc 14d9a business address street 1 7999 gateway blvd street 2 suite 300 city newark state ca zip 94560 business phone 5107448000 mail address street 1 7999 gateway blvd street 2 suite 300 city newark state ca zip 94560 sc 14d9a 1 a152091720sc14d9ahtm sc 14d9a security exchange commission washington dc 20549 schedule 14d9a rule 14d101 solicitationrecommendation statement section 14d4 security exchange act 1934 amendment no 6 depomed inc name subject company depomed inc name person filing statement common stock par value title class security 249908104 cusip number class security james a schoeneck president chief executive officer 7999 gateway boulevard suite 300 newark california 94560 510 7448000 name address telephone number person authorized receive notice communication behalf person filing statement copy to ryan a murr esq eduardo gallardo esq james j moloney esq gibson dunn crutcher llp 555 mission street suite 3000 san francisco california 941050921 j david kirkland esq john w martin esq brian d lee esq baker botts llp 1001 page mill road building one suite 200 palo alto california 943041007 check box filing relates solely preliminary communication made commencement tender offer amendment no 6 schedule 14d9 amends supplement solicitationrecommendation statement schedule 14d9 a amended time time “schedule 14d9” originally filed depomed inc california corporation “depomed” “company” security exchange commission the “sec” september 14 2015 last amended amendment no 5 filed sec november 4 2015 except specifically noted herein information set forth schedule 14d9 remains unchanged capitalized term used defined amendment no 5 meaning ascribed schedule 14d9 item 9 exhibit item 9 hereby amended supplemented adding following exhibit a13 message employee depomed inc dated november 6 2015 incorporated reference depomed inc’s schedule 14a filed november 6 2015 a14 excerpt depomed inc’s q3 2015 earnings call incorporated reference depomed inc’s schedule 14a filed november 10 2015 a15 corporate presentation dated november 2015 incorporated reference depomed inc’s schedule 14a filed november 18 2015 a16 press release issued depomed inc november 19 2015 respect withdrawal horizon pharma plc’s offer acquire depomed inc filed herewith 1 signature due inquiry best knowledge belief certify information set forth schedule 14d9 true complete correct depomed inc by s matthew m gosling name matthew m gosling title senior vice president general counsel dated november 20 2015 2 ex99a16 2 a152091720ex99da16htm exa16 exhibit a16 press release depomed comment horizon withdrawal offer acquire company withdrawal follows court ruling enjoining horizon’s exchange offer proxy solicitation newark calif nov 19 2015 prnewswire — depomed inc nasdaq depo “depomed” “company” today issued following statement regarding horizon pharma plc’s nasdaq hznp “horizon” decision withdraw acquisition proposal withdrawal follows ruling today santa clara county superior court enjoining horizon pharma’s exchange offer proxy solicitation based horizon’s misuse depomed’s confidential information depomed’s board management team committed enhancing longterm value look forward continuing execute strategy delivering significant sustainable return shareholder example nucynta franchise is view transformational value driver depomed significantly increase depomed’s ebitda cash flow 2015 beyond ultimately strongly believe successfully executed acquisition commercialization strategy depomed bright future independent company thank shareholder input support throughout process importantly want thank employee relentless focus dedication patient family physician provider payer serve morgan stanley co llc leerink partner llc serving financial advisor depomed gibson dunn crutcher llp baker botts llp serving legal counsel depomed depomed specialty pharmaceutical company commercializes product pain neurology related disorder nucynta® franchise includes nucynta® er tapentadol extended release tablet indicated management pain including neuropathic pain associated diabetic peripheral neuropathy dpn severe enough require daily aroundtheclock longterm opioid treatment nucynta® tapentadol immediate release version tapentadol management moderate severe acute pain adult gralise® gabapentin oncedaily treatment approved management postherpetic neuralgia cambia® diclofenac potassium oral solution nonsteroidal antiinflammatory drug indicated acute treatment migraine attack without aura adult 18 year age older zipsor® diclofenac potassium liquid filled capsule nonsteroidal antiinflammatory drug indicated relief mild moderate acute pain adult lazanda® fentanyl nasal spray intranasal fentanyl drug used manage breakthrough pain adult 18 year age older already routinely taking opioid pain medicine aroundtheclock cancer pain gralise nucynta er various partner product candidate formulated depomed’s proven proprietary acuform® drug delivery technology additional information depomed may found wwwdepomedcom forwardlooking statement statement historical fact contained release forwardlooking statement involve risk uncertainty including limited to related depomed’s prospect standalone business depomed’s business strategy expectation regarding depomed’s future financial result ability create shareholder value expectation regarding anticipated growth future contribution potential nucynta risk detailed company’s security exchange commission “sec” filing including company’s annual report form 10k year ended december 31 2014 recent quarterly report form 10q inclusion forwardlooking statement regarded representation company’s plan objective expectation achieved cautioned place undue reliance forwardlooking statement speak date hereof company undertakes obligation publicly release result revision forwardlooking statement may made reflect event circumstance date hereof reflect occurrence unanticipated event investor contact depomed inc august j moretti chief financial officer 5107448000 amorettidepomedcom christopher keenan vp investor relation corporate communication 5107448000 ckeenandepomedcom innisfree ma incorporated larry miller jonathan salzberger scott winter 2127505833 medium contact joele frank wilkinson brimmer katcher eric brielmann 4158693950 andy brimmer averell withers adam pollack 2123554449 graphic 3 g2091720mmi001jpg graphic begin 644 g2091720mmi001jpg mcx 02d91 0 8 vp hpdh dphqd0px mqx6q9 f2rh3dphvrcd0rcl0 c2t42cd0w mvp 0lpqt0t2i3t3t3t3t3t3t3t3t3t m3t3t3t3t3t3t3t3wp 1 l 2 a q0 mp 04 0 0 p00h0 m1 p p4 m 0 0 011a4uarqdtqp152t dvrd ma81heb7ja6axbbi3e66eyb9fjci6fizbijksm6vmbynlq7 mqcrm3u76uc9vnbx3eynhzkqotwgz0 p p 0 0 0 p00h0 m1 0 0 0w q2qa40a1bh1h2s4o 58g1a8de181hf mric4vsyd1492e4u155e865ic95f9vaigt79wezh ma8bfdi4e97ffhjdigjfjlktmwnfzplqrgtm4 mu7vgxndygzgjotwgzh 1 q pvbbba mu5uf3i e11 2ghktw6skyixwsb0o qjox9k932zxel maqrujoxs42r6lvc9h86wc9xz mwafhlbzxs136ap yitnztunqbn5pzlnua2np myelif1cka63z91uq vo098ga5uuaxp2z5i5cjrdjguagtgpsxb97e l4 mz9pzfh1xyueclng0vpbbzjjrcyl4z24d6zt mvmyqw5vj8c43mmb62d0q0kci6heakhu4 mfxfuu8csba k3uqpvmxi5u r1hq50nu2e2a4gkzg2k5itozate75 mpq6vrq71a6gmlkks27 zqph78782i24wuvcia7a mjv3bl3t5mxlwtloujnbw1en4crlvthyisgub mopmf1lt5a2boknvemivymnkh55rp12e4b0xu3 mw45b3mbn29yyobgv4bkvgo9m9x255x5jir2nt m6g97m8tbw1kr6o4nl4goocfvnlowh74i mohqm37veymt5f7b3mkfxnd25nva7m74ot50u62 ovvx6gx6z 57lf7ev59fbn ma0mtu3du05grmzfo557mmmq9yjd9uqtirm mmfnn98hezlqk nfck875mrx574qvs3itwwmul8jutf6k mqiiusqkey36k77zmdfnp6keakm2tjxe2 m0x9phzuozkvjuiixclhtsoscvqg kg96apuo4gezb m8kmhpdwkv1s8z52itxjrzmh7uvdaroogm7kf mdpwoit4h3bx 9pykbv1t33h9hc62ujnw mo9mt4ka0h r3 6ktj1yfk4nayunsxzxekek920 mrcaduz5uui6gyg8lytez45sq2ae61xnmv9 mmlpljyf5dh0ukw q2ae7gm6cv5fc agr2w1z m7d zxs9zj4qn8j20mqxmauqdtw0 mdenbxqf1a0mme5z6fayvk0aakzzz3 2r6vbzsay1 mu547gcbn220db1g5j3abhhrfzoovaa3c1zh mwove6r7 bwfjnu8cjzzx7f16cajqxmlwp muk8rf2x3gxcxbjnieonwp ms56j5sxtz50wno dqmx23qjl23u0c3hw2abnbbefgg57 mjy7lxn59mu8q 6bvshgvrcr9c021viflphmj6d72b0 mrn yutg3 ukskgpxnjwpfy3jwhhuh5b mo xbwdqsbwphumtqkum65ogr1sduf6 mk229dcgrgtkkhvas6zr a543i2y9tu0fe myz5gn6udeo05j6mrwagp m9pmwjgr4crg4gb3iqm5ie8pkddt4oofzoxjmm mtbw18t0 2de7i8qdge2isehce6elkry8kp8 mni2luzwnxcn39arm6aoan 9o2qozclp9 mzihqpxmw52 c5hrm4ct8t95uzhjixdti mj99a 6mv6i3ytc6d9hsao8xy5m85la2 mdlxqqce76k34vkzal3e3ck4jj2px0d6i5 mjehke9w61eyx1gid8qbjd8irhiz30qrkzh m2t4mam7wo8vmh2vabz ka1 6dd4qh8wtxz5 m16mkr2ygj85jmjtun0c3k36slywgzlt45fvwnxtzsn mgw7kwjz fihhhxpd2bhjc hhnldcbcshk1grjze64 mu1251j 8ibc1rrqj4hr52 m39vz wec 6z0g6574jraejpm4lvabv mfkvd1b1t50hq3z0phhhh ivnf0vmwbcze8ny67rtsphhhjn9dscvqo5qa86lcn8vc mn8qp0pbbdie2mhdp6l7hq1jdj5s7fkuqi m1112 1110 4444 1110 4444 1110 4444 v0 end